[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352635-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352635-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","urachal-signet-ring-cell-carcinoma-a-clinicopathological-analysis-of-28-cases","Urachal Signet Ring Cell Carcinoma - A Clinicopathological Analysis of 28 Cases","","Urachal carcinoma is a rare bladder malignancy comprising less than 1% of cases, with the signet-ring cell subtype being unusually aggressive and diagnostically difficult. A retrospective multi-institutional analysis used data from BC Cancer and MD Anderson Cancer Center (1989–2023), comparing 28 signet-ring cell carcinoma cases with 47 non-SRCC controls. SRCC showed more advanced stage and higher recurrence, with inferior cancer-specific and survival outcomes despite multimodal treatment. Signet-ring cell presence independently predicts poor prognosis, supporting subtype-focused therapeutic strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/urachal-signet-ring-cell-carcinoma-a-clinicopathological-analysis-of-28-cases/352635/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/urachal-signet-ring-cell-carcinoma-a-clinicopathological-analysis-of-28-cases/352635.png","ImageObject",300,407,{"name":42,"@type":43},"Connor ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is urachal signet ring cell carcinoma and why is it important clinically?","Question",{"text":63,"@type":64},"It is a rare urachal carcinoma subtype characterized by signet-ring cells and aggressive behavior. The document highlights its diagnostic and therapeutic challenges and its role in poor outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study conducted and what patient groups were compared?",{"text":68,"@type":64},"The study is a retrospective review from 1989 to 2023 using BC Cancer and MD Anderson Cancer Center data. It compared 28 SRCC cases with 47 non-SRCC urachal carcinoma cases.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical and survival differences were observed between SRCC and non-SRCC?",{"text":72,"@type":64},"SRCC was associated with advanced stage at presentation and a higher recurrence rate. Survival analysis showed worse five-year cancer-specific survival in the SRCC cohort, despite treatment including surgery and more frequent adjuvant chemotherapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352635,1790276349,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nUrachal Signet Ring Cell Carcinoma: A Clinicopathological Analysis of 28 Cases  \nNatalie South 1,†, Ioana Maria Mihai 2,3,†, Vickie Wang 4, Mehdi Agoumi 3,5, Charles Guo 6 and Gang Wang 2,3, *  \nReceived: 24 January 2026  \nRevised: 26 February 2026  \nAccepted: 5 March 2026  \nPublished: 7 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 School of Medicine, University of Medicine and Health Sciences, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland  \n2 Department of Pathology and Laboratory Medicine, BC Cancer, Vancouver, BC V6T 1Z1, Canada  \n3 Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada  \n4 Faculty of Science, University of British Columbia, Vancouver, BC V6T 1Z4, Canada  \n5 Department of Pathology and Laboratory Medicine, Surrey Memorial Hospital, Surry, BC V3V 1Z2, Canada  \n6 Department of Pathology, MD Anderson Cancer Center, Houston, TX 77030, USA  \n* Correspondence: [gang.wang1@bccancer.bc.ca](gang.wang1@bccancer.bc.ca)[ ](gang.wang1@bccancer.bc.ca)† These authors contributed equally to this work.  \nSimple Summary  \nUrachal carcinoma of the bladder is a rare malignancy that develops from urachal remnants. The signet ring cell subtype is a particularly rare and aggressive subtype that often presentsa diagnostic challenge. This study analyzed a multi-institutional cohort of 75 patients, comparing 28 cases of urachal signet ring cell carcinomas with 47 cases of different urachal carcinomas subtypes. Our results show that the signet ring cell subtype is associated with advanced disease at diagnosis and a higher recurrence rate compared to the control group. Despite aggressive surgical management and chemotherapy, patients with this subtype had lower survival rates. Overall, the presence of signet ring cells is a strong independent predictor of poor prognosis. These results highlight the importance of implementing dedicated clinical strategies and therapeutic interventions targeted to this specific histological profile.  \nAbstract  \nBackground: Urachal carcinoma is a rare malignancy comprising less than 1% of all bladder cancers. The signet-ring cell subtype is particularly aggressive and poses significant diagnostic and therapeutic challenges. Methods: A retrospective review of urachal carcinoma cases from 1989 to 2023 was conducted using data from BC Cancer and MD Anderson Cancer Center. The study analyzed 75 patients, including 28 signet-ring cell carcinoma (SRCC) cases and a control group of 47 non-SRCC cases, to compare survival patterns, treatment outcomes, and histopathological features. Results: Clinically, the SRCC subtype was associated with advanced stage at presentation (pT3/pT4) and a higher recurrence rate (82% vs. 53%; p = 0.01) . Survival analysis demonstrated worse outcomes for the SRCC cohort, with a five-year cancer-specific survival (CSS) of 39% compared to 64% in thenon-signet group (p = 0.053) . Partial cystectomy remained the primary surgical approach for both cohorts. Adjuvant chemotherapy was administered more often in SRCC cases (86% vs. 47%) . Conclusions: By providing a comprehensive multi-institutional analysis, this study establishes urachal SRCC as a distinct clinical entity with a strong independent prognostic significance. Despite aggressive multimodal management, it carries a poorer prognosis compared to urachal non-SRCC, emphasizing the need for subtype-specific therapeutic guidelines.  \nKeywords: urachus; carcinoma; bladder; urachal signet-ring cell carcinoma; case series  \n1. Introduction  \nUrachal carcinoma is a rare malignancy originating from urachal remnants, representing less than 1% of all bladder cancers [1–3] . The urachus is a tubular structure extending from the urinary bladder to the umbilicus during fetal development. Typ","cbCaii7KItlQ220y","https://ap.wps.com/l/cbCaii7KItlQ220y","pdf",1452901,12,"English","# Introduction\n## Materials and Methods\n### Patients","[{\"question\":\"What is urachal signet ring cell carcinoma and why is it important clinically?\",\"answer\":\"It is a rare urachal carcinoma subtype characterized by signet-ring cells and aggressive behavior. The document highlights its diagnostic and therapeutic challenges and its role in poor outcomes.\"},{\"question\":\"How was the study conducted and what patient groups were compared?\",\"answer\":\"The study is a retrospective review from 1989 to 2023 using BC Cancer and MD Anderson Cancer Center data. It compared 28 SRCC cases with 47 non-SRCC urachal carcinoma cases.\"},{\"question\":\"What clinical and survival differences were observed between SRCC and non-SRCC?\",\"answer\":\"SRCC was associated with advanced stage at presentation and a higher recurrence rate. Survival analysis showed worse five-year cancer-specific survival in the SRCC cohort, despite treatment including surgery and more frequent adjuvant chemotherapy.\"}]","Urachal Signet Ring Cell Carcinoma - A Clinicopathological Analysis of 28 Cases | PDF",1790100564,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86b8635dc2f273fe6c68a7a9ef580c1c.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69bde809dff6e9d5f34da079a86d4365.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a3249b129b60f0fdb4d22d407a6075a.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76a6a671758ace189e116bc222f9a193.webp",980,1385]